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Transmission of an undiagnosed cancer with solid organ
transplantation is a rare but dreadful event. In this paper
the authors report the transmission of an undiagnosed
sarcoma to recipients of kidney and liver grafts procured
in a Maastricht category 3 non-heart beating donor. To
the authors’ knowledge this case is the ﬁrst report of such
a transmission with a liver graft procured in a non-heart
beating donor. The cancer transferal was diagnosed 1 year
after transplantation in the recipients of the liver and of
one kidney. The liver recipient died from multiple organ
failure after a failed attempt of tumor resection. The kid-
ney recipient underwent immunosuppression withdrawal
and transplantectomy. Non-heart beating donors should
not be particularly at risk for undiagnosed cancer trans-
mission if the procurement is performed according to the
same rules of careful inspection of the abdominal and
thoracic organs. After diagnosis of donor cancer transmis-
sion, kidney recipients should have the graft removed, and
immunosuppression should be interrupted. The manage-
ment of liver graft recipients is very difﬁcult in this setting,
and long-term survival was very rarely reported. (Liver
Transpl 2005;11:696-699.)
Transmission of cancer with solid organ transplan-tation is a rare but dreadful event.1,2 To limit the
risk of occurrence of this severe complication, brain
dead patients with past history of malignant disease are
often excluded from the donor pool, with the relative
exception of patients with cerebral nervous system
malignant tumors.3,4 However, this policy does not
eliminate the risk of an undiagnosed donormalignancy,
and case reports of undiagnosed cancer transmission
have published.5
As the transplant community faces an increas-
ing donor organ shortage, the use of marginal
donors, including older donors or non-heart beating
donors (NHBDs), is now more widely accepted to
partially cover the need of organs.6 In this paper the
authors report the transmission of an undiagnosed
sarcoma to recipients of kidney and liver grafts pro-
cured in a Maastricht category 3 NHBD. To the
authors’ knowledge this case is the ﬁrst report of such




The donor was a 60-year-old woman without any his-
tory of malignant disease. She suffered from deep hyp-
oxia due to a severe acute asthma crisis. She was found
in cardiac arrest and circulation was successfully
restored after tracheal intubation. She suffered from
deep cerebral anoxia. Cortical electro-encephalogram
remained isoelectric after 7 days. She was proposed as
Maastricht category 3 NHBD, and both kidneys and
liver were procured after 5 minutes of cardiac arrest
after life support withdrawal in the operative room. No
tumor was found during the procurement, which
includedmedian laparotomy and sternotomy. No post-
mortem autopsy was performed. The liver was locally
transplanted and the kidneys were allocated to recipi-
ents in other centers according to the best matching.
Liver Recipient
The recipient of the liver was a 53-year-oldmale patient
with hepatitis C virus cirrhosis and a 3-cm hepatocel-
lular carcinoma.While on the waiting list he underwent
chemoembolization and was deemed the best suitable
recipient for thisNHBD liver. The transplantation pro-
cedure and the early postoperative periodwere unevent-
ful. The tumor was completely necrotic at pathology.
The patient was discharged at postoperative day 15 and
his evolution was uncomplicated until postoperative
month 13, when he presented with cholestasis. Liver
ultrasonography and computed tomography showed a
large necrotic lesion within the left liver (Fig. 1). Lapa-
rotomy conﬁrmed a large tumor that was proven a
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sarcoma at frozen section. R0 resection was impossible,
and a palliative hepatico-jejunostomy was performed.
The patient died 5 days later from multiorgan failure.
Deﬁnitive histological sections conﬁrmed a spindle cell
sarcoma (Fig. 2). Immunohistochemistry indicated
that the cells were diffusely strongly positive for vimen-
tin, negative for cytokeratins, negative for S100 protein,
negative for CD31 and CD34, negative for desmin and
CD117, focally faintly positive for smoothmuscle actin
and focally positive for CD10. Fluorescence in situ
hybridization showed an XX pattern in 74.5% of the
nuclei (with polyploidy for the X chromosome in the
tumor cells), establishing the probable donor (female)
origin of the sarcoma (Fig. 3).
Kidney Recipients
One kidney was removed 10 days after transplantation
because of primary nonfunction. Pathology did not
ﬁnd evidence of tumor, and the recipient did not
develop cancer in 18 months of follow-up. The recipi-
ent of the second kidney had to undergo transplantec-
tomy 1 year after transplantation for a malignant graft
tumor that proved to be a spindle cell sarcoma compa-
rable to the tumor found in the liver recipient.
Discussion
Transmission of cancer from organ donor to recipient is
a sporadic but dreadful complication of solid organ
transplantation. Most cases occurred in the pioneering
years of organ transplantation, when the risk of cancer
transmission was not known.1,2,7 Currently, past his-
tory of cancer has become a contraindication to organ
harvesting, with the relative exception of some tumors
with very low risk of dissemination, such as low-grade
skin cancers, carcinoma in situ, or primary central ner-
vous system tumors.3,4,8 Despite this policy, cases of
undiagnosed donor cancer transmission with the graft
are still regularly published.5,9.10 In this paper, the
authors report what they believe is the ﬁrst case of
cancer transmission with grafts harvested in a NHBD
in the modern age of organ transplantation. In the
1960s, NHBDs were regularly organ donors, and cases
of transmission of cancer with kidney transplants were
reported at that time.1,2,7 The occurrence of the same
tumor in both recipients at nearly the same moment
after transplantation, together with the demonstration
Figure 1. Computed tomography of the liver recipient
showing the large necrotic tumor localized in the left liver
lobe.
Figure 2. Surgical biopsy of the liver graft tumor showing
a spindle cell sarcoma (Hematoxylin & eosin stain; origi-
nal magniﬁcation 200).
Figure 3. Fluorescence in situ hybridization of the liver
graft tumor showing a majority of nuclei with only green
signals (chromosome X). The chromosome Y probe
(DYZ3) is labeled in red. Note also the presence of
polyploid cells for the X chromosome.
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of the female (XX) character of the tumor cells in a male
(XY) recipient, proved that this sarcoma was present
and undiagnosed in the donor at the time of organ
procurement. The primary lesion is not known, and it is
probable that both lesions in the liver and in the kidney
grafts were metastases that slowly developed in the
recipients over several months before being diagnosed.
The absolute risk of undiagnosed cancer transmis-
sion with solid organ transplantation is low but real. It
has even been reported that in the actual organ shortage
era some donors with a past history of (cured) cancer
could be exceptionally considered for donation.11 This
policy remains highly controversial, especially with the
growing number of reported cases of cancer transmis-
sion with organ transplantation. Some cancers undiag-
nosed before organ donation may be discovered during
multiorgan harvesting, and this discovery should inter-
rupt the procurement. However most undiagnosed
cancers are infraclinical, and there is no way to be abso-
lutely sure that a speciﬁc donor has no malignancy.
Donor autopsy has been proposed,1 but it is rarely per-
formed and may not avoid missing some small malig-
nant lesions. Due to the increased incidence of cancer
with age, this risk should be increased in older donors,
who currently are more often proposed for donation.
To the authors’ view, there is no reason why NHBDs
should be particularly at risk of cancer transmission if
the procurement is performed according to the same
rules of careful inspection of the abdominal and tho-
racic organs. In the case described in this paper, the
procurement was performed by an experienced certiﬁed
transplant surgeon, and the authors’ group is verymuch
aware of this potential problem, as some cases of cancer
transmission have already been encountered in the
authors’ experience.
Management of organ recipient with transplanted
donor cancer is difﬁcult, as cancers might develop rap-
idly and aggressively in immunosuppressed patients.12
This fact was at ﬁrst explained by the so-called
“immune surveillance hypothesis” that suggested that
the immune system controls cancer development.
However, the defective immune surveillance theory
may not explain all the features of cancer behavior and
development in immunosuppressed patients. It has
recently been demonstrated that calcineurin inhibitors
may directly inﬂuence cancerous cells and may induce
tumor progression by a cell-autonomous mechanism
that may be linked to the production of transforming
growth factor- (TGF-).13,14 On the contrary, it was
proposed that mTOR inhibitors and mycophenolate
mofetil–based immunosuppressionmight be beneﬁcial
in organ recipients with cancer.14 These data have to be
further demonstrated by larger series.
Once a transmitted cancer is diagnosed in a kidney
graft recipient, the graft should be removed with initi-
ation of dialysis, and immunosuppression should be
interrupted. This management, in some cases with spe-
ciﬁc chemotherapy, was successful in the majority of
published cases of cancer transmission with kidney
transplantation.1 For liver transplant recipients, the sit-
uation is more complicated and management may
depend on the delay between donor cancer diagnosis
and liver transplantation. If the cancer is diagnosed in
the donor shortly after graft reperfusion, emergency
retransplantation has been proposed.15 However, this
policy does not allow immunosuppression interrup-
tion, and the recipient may develop generalized cancer
if malignant cells have already left the graft at the time
of retransplantation.5 Reducing immunosuppression
and switching to a calcineurin inhibitor– free regimen,
in addition to radical surgery and/or adjuvant systemic
chemotherapy in selected cases, could be justiﬁed
according to the tumor type and to the patient charac-
teristics. In cases in which the donor cancer was diag-
nosed several months after transplantation, complete
interruption of immunosuppression was proposed to
induce cancer rejection.16 This policy, in addition to
systemic chemotherapy and retransplantation as the
rejection process induces liver graft failure, was success-
fully reported.16 However, cases of successful liver
retransplantation are rare,17 and the management of
liver recipients diagnosed with transplanted malignant
tumor remains highly challenging.
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